Karol M Pencina1, George Thanassoulis2, John T Wilkins3, Ramachandran S Vasan4, Ann Marie Navar5, Eric D Peterson6, Michael J Pencina7, Allan D Sniderman8. 1. Section on Men's Health Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: kpencina@bwh.harvard.edu. 2. Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada. 3. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 4. Framingham Heart Study, Section of Preventive Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts; Section of Cardiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts; Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts. 5. Duke Clinical Research Institute, Durham, North Carolina. 6. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 7. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 8. Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada.
Abstract
BACKGROUND: Extended elevations of non-high-density lipoprotein cholesterol (non-HDL-C) across a lifespan are associated with increased risk of cardiovascular disease (CVD). However, optimal testing intervals to identify individuals with high lipid-related CVD risk are unknown. OBJECTIVES: This study determined the extent to which lipid levels in young adulthood predict future lipid trajectories and associated long-term CVD risk. METHODS: A sample of 2,516 Framingham Offspring study participants 25 to 40 years of age free of CVD and diabetes had their non-HDL-C progression modeled over 8 study examinations (mean follow-up 32.6 years) using group-based methods. CVD risk based on 25 to 30 years of follow-up was evaluated using Kaplan-Meier analyses for those with mean non-HDL-C ≥160 mg/dl ("high") and <130 mg/dl ("low") at the first 2 examinations. Levels of non-HDL-C for participants on lipid treatment were adjusted by nonparametric algorithm. RESULTS: The trajectories of the lipid levels were generally stable over the 30-year life course; mean non-HDL-C measured in young adulthood were highly predictive of levels later in life. Individuals could be reliably assigned to high and low non-HDL-C groups based on 2 measurements collected between 25 to 40 years of age. Overall, 80% of those with non-HDL-C ≥160 mg/dl at the first 2 exams remained in the high group on subsequent 25-year testing, whereas 88% of those with non-HDL-C <130 mg/dl remained below 160 mg/dl. Those with high non-HDL-C in young adulthood had a 22.6% risk of CVD in the next 25 years as compared with a 6.4% risk in those with low non-HDL-C. CONCLUSIONS: Most adults with elevated non-HDL-C early in life continue to have high non-HDL-C over their life course, leading to significantly increased risk of CVD. The results demonstrate that early lipid monitoring before 40 years of age would identify a majority of those with a high likelihood for lifetime elevated lipid levels who also have a high long-term risk for CVD. This information could facilitate informed patient-provider discussion about the potential benefits of preventive lipid-lowering efforts during the early midlife period.
BACKGROUND: Extended elevations of non-high-density lipoprotein cholesterol (non-HDL-C) across a lifespan are associated with increased risk of cardiovascular disease (CVD). However, optimal testing intervals to identify individuals with high lipid-related CVD risk are unknown. OBJECTIVES: This study determined the extent to which lipid levels in young adulthood predict future lipid trajectories and associated long-term CVD risk. METHODS: A sample of 2,516 Framingham Offspring study participants 25 to 40 years of age free of CVD and diabetes had their non-HDL-C progression modeled over 8 study examinations (mean follow-up 32.6 years) using group-based methods. CVD risk based on 25 to 30 years of follow-up was evaluated using Kaplan-Meier analyses for those with mean non-HDL-C ≥160 mg/dl ("high") and <130 mg/dl ("low") at the first 2 examinations. Levels of non-HDL-C for participants on lipid treatment were adjusted by nonparametric algorithm. RESULTS: The trajectories of the lipid levels were generally stable over the 30-year life course; mean non-HDL-C measured in young adulthood were highly predictive of levels later in life. Individuals could be reliably assigned to high and low non-HDL-C groups based on 2 measurements collected between 25 to 40 years of age. Overall, 80% of those with non-HDL-C ≥160 mg/dl at the first 2 exams remained in the high group on subsequent 25-year testing, whereas 88% of those with non-HDL-C <130 mg/dl remained below 160 mg/dl. Those with high non-HDL-C in young adulthood had a 22.6% risk of CVD in the next 25 years as compared with a 6.4% risk in those with low non-HDL-C. CONCLUSIONS: Most adults with elevated non-HDL-C early in life continue to have high non-HDL-C over their life course, leading to significantly increased risk of CVD. The results demonstrate that early lipid monitoring before 40 years of age would identify a majority of those with a high likelihood for lifetime elevated lipid levels who also have a high long-term risk for CVD. This information could facilitate informed patient-provider discussion about the potential benefits of preventive lipid-lowering efforts during the early midlife period.
Authors: Shuaib M Abdullah; Laura F Defina; David Leonard; Carolyn E Barlow; Nina B Radford; Benjamin L Willis; Anand Rohatgi; Darren K McGuire; James A de Lemos; Scott M Grundy; Jarett D Berry; Amit Khera Journal: Circulation Date: 2018-11-20 Impact factor: 29.690
Authors: Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page Journal: J Am Coll Cardiol Date: 2017-10-30 Impact factor: 24.094
Authors: Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis Journal: J Lipid Res Date: 2018-05-16 Impact factor: 5.922
Authors: George Thanassoulis; Ken Williams; Kathleen Kimler Altobelli; Michael J Pencina; Christopher P Cannon; Allan D Sniderman Journal: Circulation Date: 2016-03-04 Impact factor: 29.690
Authors: Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Fabian J Brunner; Christoph Waldeyer; Francisco Ojeda; Veikko Salomaa; Frank Kee; Susana Sans; Barbara Thorand; Simona Giampaoli; Paolo Brambilla; Hugh Tunstall-Pedoe; Marie Moitry; Licia Iacoviello; Giovanni Veronesi; Guido Grassi; Ellisiv B Mathiesen; Stefan Söderberg; Allan Linneberg; Hermann Brenner; Philippe Amouyel; Jean Ferrières; Abdonas Tamosiunas; Yuriy P Nikitin; Wojciech Drygas; Olle Melander; Karl-Heinz Jöckel; David M Leistner; Jonathan E Shaw; Demosthenes B Panagiotakos; Leon A Simons; Maryam Kavousi; Ramachandran S Vasan; Robin P F Dullaart; S Goya Wannamethee; Ulf Risérus; Steven Shea; James A de Lemos; Torbjørn Omland; Kari Kuulasmaa; Ulf Landmesser; Stefan Blankenberg Journal: Lancet Date: 2019-12-03 Impact factor: 79.321
Authors: Yuan Wang; Eric Yuk Fai Wan; Ivy Lynn Mak; Margaret Kay Ho; Weng Yee Chin; Esther Yee Tak Yu; Cindy Lo Kuen Lam Journal: PLoS One Date: 2022-01-27 Impact factor: 3.240
Authors: Line Gaundal; Mari C W Myhrstad; Lena Leder; Marte Gjeitung Byfuglien; Terje Gjøvaag; Ida Rud; Kjetil Retterstøl; Kirsten B Holven; Stine M Ulven; Vibeke H Telle-Hansen Journal: Br J Nutr Date: 2020-09-02 Impact factor: 3.718